The high fragmentation of nuclear circulating DNA (cirDNA) relies on chromatin organization
and protection or packaging within mononucleosomes, the smallest and the most stabilized …

Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

Nucleosome positioning is involved in many gene regulatory processes happening in the
cell, and it may change as cells differentiate or respond to the changing microenvironment in …

Purpose Conventional genetic analyzers require surgically obtained tumor tissues to confirm
the molecular diagnosis of diffuse glioma. Recent technical breakthroughs have enabled …

In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through
accurate assessment of minimal residual disease (MRD) and therapeutic response …

The effectiveness of cancer treatment strongly depends on the early detection of the
disease. Currently, the most common diagnostic method, tissue biopsy, takes time and can …

Follicular lymphoma (FL) is the second most frequent non-Hodgkin lymphoma accounting
for 10-20% of all lymphomas in western countries. As a clinically heterogeneous cancer, FL …

Background Fragmentomics, the investigation of fragmentation patterns of cell-free DNA
(cfDNA), has emerged as a promising strategy for the early detection of multiple cancers in …

Whole-genome bisulfite sequencing (BS-Seq) measures cytosine methylation changes at
single-base resolution and can be used to profile cell-free DNA (cfDNA). In plasma …

Pancreatic cancer (PC) continues to pose a major clinical challenge. There has been little
improvement in patient survival over the past few decades, and it is projected to become the …